Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
22 October 2024 | Story Jacky Tshokwe | Photo Supplied
Dr Rosaline Sebolao
Dr Rosaline Sebolao, Teaching and Learning Manager in the Faculty of The Humanities at the University of the Free State, has been recognised with an award from Higher Education Resource Services South Africa (HERS-SA).

The University of the Free State (UFS) is proud to announce that Dr Rosaline Sebolao, our Teaching and Learning Manager in the Faculty of The Humanities, has been recognised with an award from Higher Education Resource Services South Africa (HERS-SA). At the ceremony, Dr Sebolao was one of the top five finalists for her exceptional contributions to higher education, particularly in academic administration.

The HERS-SA Award celebrates outstanding women in academic administration, acknowledging their crucial role in supporting and transforming the higher education landscape. According to Dr Sebolao, “The significance of this award lies in its developmental and transformative impact.” She explains that it highlights the essential contributions made by women in academic administration and encourages gender transformation within universities. This recognition empowers women to take on leadership roles, shifting the focus beyond traditional academic achievements.

Award recipients are selected based on a minimum of five years of demonstrated leadership in academic administration. Dr Sebolao’s innovative leadership practices, her contributions to institutional performance, her peer mentoring, and community engagement were all key criteria in her selection. Her mentoring efforts, particularly through school visits and support for underprivileged students, have made a lasting impact on the community and her peers.

Reflecting on the honour of receiving the award, Dr Sebolao describes it as “humbling and exciting”. She felt especially inspired as a mentor, noting that this recognition has the potential to encourage young women and men to strive for excellence in their academic and administrative pursuits.

Achievements leading to the award

In her role as Teaching and Learning Manager, Dr Sebolao has made significant contributions to both students and academics at the UFS. She has initiated several impactful projects, including the establishment of student indabas and entrepreneurial initiatives aimed at addressing graduate unemployment. Her commitment to improving communication led to the launch of a faculty newsletter, enhancing engagement among academics.

Among her most notable achievements is the Scholarship of Teaching and Learning (SoTL) project, which culminated in the UFS’ inaugural SoTL seminar in July 2024. She also spearheaded the Humanities Excellence Awards, encouraging faculty to pursue greater academic and research recognition. Her dedication to engaged scholarship extended beyond the university, resulting in community collaborations such as the establishment of a school library in Ikgomotseng, promoting literacy and education among local learners.

Dr Sebolao’s academic journey began after transitioning from the business sector to academia in 2013. Her experience in roles such as Peer Mentorship Coordinator and Teaching and Learning Coordinator at the Central University of Technology, and later as Manager of Special Projects in Teaching and Learning, helped shape her leadership style. She joined the UFS during the challenging COVID-19 period, a time that also marked some of her greatest achievements.

One of the key challenges that Dr Sebolao faced was overcoming the isolated nature of work within the faculty. By fostering a collaborative culture, she succeeded in promoting teamwork and innovation across departments. This approach not only improved institutional collaboration, but also strengthened her professional impact.

Dr Sebolao’s relationship with HERS-SA has been instrumental in her development as a leader in higher education. Since participating in the HERS-SA Academy in 2018, she has connected with influential women in the sector and solidified her commitment to mentoring others. Winning this award affirms the importance of mentoring and paves the way for future leaders in higher education.

Looking to the future, Dr Sebolao aspires to continue championing gender transformation in leadership. She aims to empower more women, particularly black women, to take on leadership roles within academia. Her focus is on fostering community development through collaborative projects that promote sustainable living, aligning with her broader vision for teaching and learning at the UFS.

Dr Sebolao encourages young women to believe in their abilities and seek mentorship for guidance and support. She emphasises that perseverance, coupled with a strong support network, is essential to achieving leadership success in higher education.

Outside of her professional life, Dr Sebolao draws motivation from her family and community work. Guided by Ecclesiastes 9:10, which emphasises dedication in all endeavours, and inspired by Mahatma Gandhi’s words, “Be the change you want to see in the world,” she remains committed to leading with passion and integrity.

The UFS community is incredibly proud of Dr Sebolao’s achievement and her continuous contributions to academic excellence and gender transformation in higher education. This award is a testament to her tireless efforts and dedication to empowering others.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept